Last reviewed · How we verify
methylenedioxymethamphetamine
At a glance
| Generic name | methylenedioxymethamphetamine |
|---|---|
| Also known as | group therapy model |
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants (PHASE1)
- MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) (PHASE2)
- Investigation of Psychedelic Effects in Psychoactive Substances (PHASE1)
- MDMA-Assisted Therapy for Pathological Narcissism (EARLY_PHASE1)
- Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial (PHASE2)
- A Phase 2A Trial of MM402 for Autism Spectrum Disorder (PHASE2)
- MDMA in Borderline Personality Disorder (PHASE2)
- MDMA Plus Exposure Therapy for PTSD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methylenedioxymethamphetamine CI brief — competitive landscape report
- methylenedioxymethamphetamine updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI